The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Research Report 2025
Synopsis
Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
The global Age-Related Macular Degeneration (AMD) Treatment Drugs market was valued at US$ 10110 million in 2023 and is anticipated to reach US$ 14950 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Age-Related Macular Degeneration (AMD) Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-Related Macular Degeneration (AMD) Treatment Drugs.
The Age-Related Macular Degeneration (AMD) Treatment Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Age-Related Macular Degeneration (AMD) Treatment Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age-Related Macular Degeneration (AMD) Treatment Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis
Segment by Type
Aflibercept
Ranibizumab
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Age-Related Macular Degeneration (AMD) Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
The global Age-Related Macular Degeneration (AMD) Treatment Drugs market was valued at US$ 10110 million in 2023 and is anticipated to reach US$ 14950 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Age-Related Macular Degeneration (AMD) Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-Related Macular Degeneration (AMD) Treatment Drugs.
The Age-Related Macular Degeneration (AMD) Treatment Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Age-Related Macular Degeneration (AMD) Treatment Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age-Related Macular Degeneration (AMD) Treatment Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis
Segment by Type
Aflibercept
Ranibizumab
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Age-Related Macular Degeneration (AMD) Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Age-Related Macular Degeneration (AMD) Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Overview
1.1 Product Definition
1.2 Age-Related Macular Degeneration (AMD) Treatment Drugs by Type
1.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Aflibercept
1.2.3 Ranibizumab
1.2.4 Others
1.3 Age-Related Macular Degeneration (AMD) Treatment Drugs by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Value by Application (2024-2030)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Estimates and Forecasts
1.4.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue 2019-2030
1.4.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales 2019-2030
1.4.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Competition by Manufacturers
2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Age-Related Macular Degeneration (AMD) Treatment Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Product Type & Application
2.7 Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Date of Enter into This Industry
2.8 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Competitive Situation and Trends
2.8.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Age-Related Macular Degeneration (AMD) Treatment Drugs Players Market Share by Revenue
2.8.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Scenario by Region
3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region: 2019-2030
3.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region: 2019-2024
3.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region: 2025-2030
3.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region: 2019-2030
3.3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region: 2019-2024
3.3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region: 2025-2030
3.4 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Facts & Figures by Country
3.4.1 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2030)
3.4.3 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Market Facts & Figures by Country
3.5.1 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2030)
3.5.3 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2019-2030)
3.6.3 Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Facts & Figures by Country
3.7.1 Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2030)
3.7.3 Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2030)
4.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2019-2024)
4.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2025-2030)
4.1.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2030)
4.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2019-2030)
4.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2019-2024)
4.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2025-2030)
4.2.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2030)
5.1.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2019-2024)
5.1.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2025-2030)
5.1.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2030)
5.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2019-2030)
5.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2019-2024)
5.2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2025-2030)
5.2.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Ionis Pharmaceuticals, Inc
6.1.1 Ionis Pharmaceuticals, Inc Company Information
6.1.2 Ionis Pharmaceuticals, Inc Description and Business Overview
6.1.3 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.1.5 Ionis Pharmaceuticals, Inc Recent Developments/Updates
6.2 Bausch Health Companies Inc
6.2.1 Bausch Health Companies Inc Company Information
6.2.2 Bausch Health Companies Inc Description and Business Overview
6.2.3 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.2.5 Bausch Health Companies Inc Recent Developments/Updates
6.3 Regeneron Pharmaceuticals Inc
6.3.1 Regeneron Pharmaceuticals Inc Company Information
6.3.2 Regeneron Pharmaceuticals Inc Description and Business Overview
6.3.3 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.3.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
6.4 Biogen
6.4.1 Biogen Company Information
6.4.2 Biogen Description and Business Overview
6.4.3 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.4.5 Biogen Recent Developments/Updates
6.5 Novartis AG
6.5.1 Novartis AG Company Information
6.5.2 Novartis AG Description and Business Overview
6.5.3 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.5.5 Novartis AG Recent Developments/Updates
6.6 Sanofi S.A.
6.6.1 Sanofi S.A. Company Information
6.6.2 Sanofi S.A. Description and Business Overview
6.6.3 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.6.5 Sanofi S.A. Recent Developments/Updates
6.7 Bayer AG
6.7.1 Bayer AG Company Information
6.7.2 Bayer AG Description and Business Overview
6.7.3 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.7.5 Bayer AG Recent Developments/Updates
6.8 Coherus Biosciences Inc
6.8.1 Coherus Biosciences Inc Company Information
6.8.2 Coherus Biosciences Inc Description and Business Overview
6.8.3 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.8.5 Coherus Biosciences Inc Recent Developments/Updates
6.9 F. Hoffmann-La Roche Ltd
6.9.1 F. Hoffmann-La Roche Ltd Company Information
6.9.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.9.3 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.10 Apellis Pharmaceuticals Inc
6.10.1 Apellis Pharmaceuticals Inc Company Information
6.10.2 Apellis Pharmaceuticals Inc Description and Business Overview
6.10.3 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.10.5 Apellis Pharmaceuticals Inc Recent Developments/Updates
6.11 AbbVie
6.11.1 AbbVie Company Information
6.11.2 AbbVie Description and Business Overview
6.11.3 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.11.5 AbbVie Recent Developments/Updates
6.12 Pfizer Inc.
6.12.1 Pfizer Inc. Company Information
6.12.2 Pfizer Inc. Description and Business Overview
6.12.3 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.12.5 Pfizer Inc. Recent Developments/Updates
6.13 Amgen Inc.
6.13.1 Amgen Inc. Company Information
6.13.2 Amgen Inc. Description and Business Overview
6.13.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.13.5 Amgen Inc. Recent Developments/Updates
6.14 Samsung Bioepis
6.14.1 Samsung Bioepis Company Information
6.14.2 Samsung Bioepis Description and Business Overview
6.14.3 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product Portfolio
6.14.5 Samsung Bioepis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Chain Analysis
7.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Production Mode & Process
7.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Marketing
7.4.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Channels
7.4.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors
7.5 Age-Related Macular Degeneration (AMD) Treatment Drugs Customers
8 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Dynamics
8.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Trends
8.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
8.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Challenges
8.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) of Key Manufacturers (2019-2024)
Table 5. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price (US$/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Age-Related Macular Degeneration (AMD) Treatment Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Treatment Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2019-2024) & (K Dose)
Table 18. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2025-2030) & (K Dose)
Table 20. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 27. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2025-2030) & (K Dose)
Table 28. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 32. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2025-2030) & (K Dose)
Table 33. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2019-2024) & (K Dose)
Table 37. Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2025-2030) & (K Dose)
Table 38. Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 42. Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2025-2030) & (K Dose)
Table 43. Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2019-2024) & (K Dose)
Table 47. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Country (2025-2030) & (K Dose)
Table 48. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Type (2019-2024)
Table 51. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Type (2025-2030)
Table 52. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price (US$/Dose) by Type (2019-2024)
Table 59. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price (US$/Dose) by Type (2025-2030)
Table 60. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Application (2019-2024)
Table 61. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Application (2025-2030)
Table 62. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price (US$/Dose) by Application (2019-2024)
Table 69. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price (US$/Dose) by Application (2025-2030)
Table 70. Ionis Pharmaceuticals, Inc Company Information
Table 71. Ionis Pharmaceuticals, Inc Description and Business Overview
Table 72. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 73. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 74. Ionis Pharmaceuticals, Inc Recent Developments/Updates
Table 75. Bausch Health Companies Inc Company Information
Table 76. Bausch Health Companies Inc Description and Business Overview
Table 77. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 78. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 79. Bausch Health Companies Inc Recent Developments/Updates
Table 80. Regeneron Pharmaceuticals Inc Company Information
Table 81. Regeneron Pharmaceuticals Inc Description and Business Overview
Table 82. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 84. Regeneron Pharmaceuticals Inc Recent Developments/Updates
Table 85. Biogen Company Information
Table 86. Biogen Description and Business Overview
Table 87. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 89. Biogen Recent Developments/Updates
Table 90. Novartis AG Company Information
Table 91. Novartis AG Description and Business Overview
Table 92. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 94. Novartis AG Recent Developments/Updates
Table 95. Sanofi S.A. Company Information
Table 96. Sanofi S.A. Description and Business Overview
Table 97. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 98. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 99. Sanofi S.A. Recent Developments/Updates
Table 100. Bayer AG Company Information
Table 101. Bayer AG Description and Business Overview
Table 102. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 103. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 104. Bayer AG Recent Developments/Updates
Table 105. Coherus Biosciences Inc Company Information
Table 106. Coherus Biosciences Inc Description and Business Overview
Table 107. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 108. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 109. Coherus Biosciences Inc Recent Developments/Updates
Table 110. F. Hoffmann-La Roche Ltd Company Information
Table 111. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 112. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 113. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 114. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 115. Apellis Pharmaceuticals Inc Company Information
Table 116. Apellis Pharmaceuticals Inc Description and Business Overview
Table 117. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 118. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 119. Apellis Pharmaceuticals Inc Recent Developments/Updates
Table 120. AbbVie Company Information
Table 121. AbbVie Description and Business Overview
Table 122. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 123. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 124. AbbVie Recent Developments/Updates
Table 125. Pfizer Inc. Company Information
Table 126. Pfizer Inc. Description and Business Overview
Table 127. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 128. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 129. Pfizer Inc. Recent Developments/Updates
Table 130. Amgen Inc. Company Information
Table 131. Amgen Inc. Description and Business Overview
Table 132. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 133. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 134. Amgen Inc. Recent Developments/Updates
Table 135. Samsung Bioepis Company Information
Table 136. Samsung Bioepis Description and Business Overview
Table 137. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 138. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product
Table 139. Samsung Bioepis Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Age-Related Macular Degeneration (AMD) Treatment Drugs Distributors List
Table 143. Age-Related Macular Degeneration (AMD) Treatment Drugs Customers List
Table 144. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Trends
Table 145. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
Table 146. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Challenges
Table 147. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Age-Related Macular Degeneration (AMD) Treatment Drugs
Figure 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Share by Type: 2023 & 2030
Figure 4. Aflibercept Product Picture
Figure 5. Ranibizumab Product Picture
Figure 6. Others Product Picture
Figure 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Value by Application (2024-2030) & (US$ Million)
Figure 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Share by Application: 2023 & 2030
Figure 9. Hospital Pharmacy
Figure 10. Retail Pharmacy
Figure 11. Online Pharmacy
Figure 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size (2019-2030) & (US$ Million)
Figure 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (2019-2030) & (K Dose)
Figure 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price (US$/Dose) & (2019-2030)
Figure 16. Age-Related Macular Degeneration (AMD) Treatment Drugs Report Years Considered
Figure 17. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Manufacturers in 2023
Figure 18. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Share by Manufacturers in 2023
Figure 19. Global 5 and 10 Largest Age-Related Macular Degeneration (AMD) Treatment Drugs Players: Market Share by Revenue in Age-Related Macular Degeneration (AMD) Treatment Drugs in 2023
Figure 20. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 21. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2030)
Figure 23. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2030)
Figure 24. United States Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2030)
Figure 27. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2030)
Figure 28. Germany Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2019-2030)
Figure 35. China Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2030)
Figure 43. Mexico Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Brazil Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Argentina Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Colombia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Country (2019-2030)
Figure 48. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Age-Related Macular Degeneration (AMD) Treatment Drugs by Type (2019-2030)
Figure 53. Global Revenue Market Share of Age-Related Macular Degeneration (AMD) Treatment Drugs by Type (2019-2030)
Figure 54. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price (US$/Dose) by Type (2019-2030)
Figure 55. Global Sales Market Share of Age-Related Macular Degeneration (AMD) Treatment Drugs by Application (2019-2030)
Figure 56. Global Revenue Market Share of Age-Related Macular Degeneration (AMD) Treatment Drugs by Application (2019-2030)
Figure 57. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Price (US$/Dose) by Application (2019-2030)
Figure 58. Age-Related Macular Degeneration (AMD) Treatment Drugs Value Chain
Figure 59. Age-Related Macular Degeneration (AMD) Treatment Drugs Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
